Strategic partnerships Cullinan’s focus on modality-agnostic targeted therapies and recent licensing deals for velinotamig create clear opportunities for BD outreach to potential licensees, co-development partners, and JC collaborations in autoimmune diseases and cancer.

Clinical momentum With a clinical-stage pipeline and ongoing Phase 3 activities including REZILIENT3, there is potential to engage CROs, KOLs, and institutional investors, presenting prospects for partnerships, funding discussions, and advisory roles.

Therapeutic footprint The emphasis on T cell engagers for autoimmune diseases and cancer signals cross-sell potential to biotechs and pharma seeking to augment immunotherapy portfolios, particularly those targeting Sjögren’s, lupus, RA, and related autoimmune indications.

Global conferences Active participation in conferences (IASLC WCLC, ASH, Stifel forums) indicates receptive channels for physician-scientist and investor engagement; leverage these events to book meetings with decision-makers and showcase interim data.

Financial strength Strong funding runway and substantial revenue range position Cullinan as a viable partner for co-development funds, milestone-based collaborations, and strategic licensing discussions to accelerate pipeline opportunities.